Compare MPTI & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPTI | MDWD |
|---|---|---|
| Founded | 1965 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.7M | 224.6M |
| IPO Year | N/A | 2014 |
| Metric | MPTI | MDWD |
|---|---|---|
| Price | $66.07 | $17.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | 32.3K | ★ 135.7K |
| Earning Date | 02-25-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.64 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $52,989,000.00 | $20,932,000.00 |
| Revenue This Year | $13.32 | $6.97 |
| Revenue Next Year | $10.56 | $23.59 |
| P/E Ratio | $26.77 | ★ N/A |
| Revenue Growth | ★ 12.79 | 6.15 |
| 52 Week Low | $34.50 | $14.14 |
| 52 Week High | $67.52 | $22.51 |
| Indicator | MPTI | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 60.25 | 46.81 |
| Support Level | $61.50 | $17.10 |
| Resistance Level | $67.52 | $18.48 |
| Average True Range (ATR) | 2.70 | 0.72 |
| MACD | -0.31 | 0.01 |
| Stochastic Oscillator | 62.51 | 52.43 |
M-Tron Industries Inc is a diversified holding company with subsidiaries engaged in designing, manufacturing, and marketing high-engineered, high-reliability frequency and spectrum control products used to control the frequency or timing of signals in electronic circuits in various applications. The company's serving markets are aerospace and defense, space, and avionics. The company offers products such as microwave and millimeter wave filters; cavity, crystal, ceramic, lumped element, and switched filters; crystal resonators, integrated microwave assemblies, and solid-state power amplifier products.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.